| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 7.916 | 9.963 | 9.555 | 1.600 | 0 | 0 |
| Total Income - EUR | - | - | - | - | 7.916 | 9.963 | 9.555 | 1.600 | 0 | 0 |
| Total Expenses - EUR | - | - | - | - | 3.282 | 1.880 | 2.671 | 523 | 576 | 335 |
| Gross Profit/Loss - EUR | - | - | - | - | 4.634 | 8.084 | 6.884 | 1.077 | -576 | -335 |
| Net Profit/Loss - EUR | - | - | - | - | 4.396 | 7.800 | 6.598 | 1.030 | -576 | -335 |
| Employees | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Neuromind Medical S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 0 | 425 | 222 | 17 | 0 |
| Current Assets | - | - | - | - | 4.651 | 12.383 | 18.213 | 1.187 | 743 | 421 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | - | - | - | - | 4.651 | 12.383 | 18.213 | 1.187 | 743 | 421 |
| Shareholders Funds | - | - | - | - | 4.439 | 12.154 | 18.482 | 1.320 | 739 | 401 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 213 | 228 | 156 | 88 | 20 | 20 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neuromind Medical S.r.l.